3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Neoplasms
4
Head and Neck Neoplasms
3
Melanoma
2
Lung Neoplasms
2
Carcinoma, Squamous Cell
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Solid Tumor, Adult
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Advanced Solid Malignancies
1
Interventions
Gemcitabine
87
Cisplatin
66
Cystectomy
38
pembrolizumab
34
Docetaxel
25
Nivolumab
24
durvalumab
21
Paclitaxel
19
Magnetic Resonance Spectroscopy
18
Radiotherapy
17
Mitomycin
17
Carboplatin
16
atezolizumab
15
Doxorubicin
14
Cystoscopy
14
BCG Vaccine
13
Surveys and Questionnaires
12
Standard of Care
12
avelumab
11
Sunitinib
10
tremelimumab
9
Transurethral Resection of Bladder
9
Ipilimumab
9
Filgrastim
9
Blood Specimen Collection
9
Specimen Handling
8
Neoadjuvant Therapy
8
Methotrexate
8
Methods
8
Early Intervention, Educational
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urinary Bladder Neoplasms
×
Tiragolumab
×
Clear all
NCT05259319
2023-10-17
IMMUNOs-SBRT
Centre Georges Francois Leclerc
Phase 1
Unknown
92 enrolled